Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors
- 1 December 2011
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (23), 7185-7188
- https://doi.org/10.1016/j.bmcl.2011.09.066
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- The role of the c-Met pathway in lung cancer and the potential for targeted therapyTherapeutic Advances in Medical Oncology, 2011
- Targeting the cancer kinome through polypharmacologyNature Reviews Cancer, 2010
- Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical CandidatesAnti-Cancer Agents in Medicinal Chemistry, 2010
- SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivoMolecular Cancer Therapeutics, 2009
- Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Factors underlying sensitivity of cancers to small-molecule kinase inhibitorsNature Reviews Drug Discovery, 2009
- Drug development of MET inhibitors: targeting oncogene addiction and expedienceNature Reviews Drug Discovery, 2008
- Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met KinaseJournal of Medicinal Chemistry, 2008
- Hepatocyte growth factor, its receptor, and their potential value in cancer therapiesCritical Reviews in Oncology/Hematology, 2005
- c-Met as a target for human cancer and characterization of inhibitors for therapeutic interventionCancer Letters, 2004